Communiqués Cocrystal Pharma, Inc.

Actions

COCP

US19188J4094

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
1,060 ^USD	+2,91%		+29,27%	+8,27%

03/06	Cocrystal Pharma Inc. prévoit de nommer James Sapirstein au sein de son conseil d'administration	CI
03/06	Cocrystal Pharma Inc. annonce un changement de direction générale	CI

Communiqués

03/06	Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer	AQ
26/05	Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza	AQ
15/05	Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results	AQ
01/05	Cocrystal Pharma : International Conference on Antiviral Research Presentation (ICAR 2026)	PU
30/04	Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection	AQ
02/04	Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive	AQ
31/03	Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	AQ
09/03	First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment	AQ
19/02	Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026	AQ
18/12	Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus	AQ
01/12	Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference	AQ
17/11	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	AQ
14/11	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	AQ
30/10/25	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
27/10/25	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program	AQ
09/10/25	Cocrystal Pharma : Investor Presentation	PU
02/10/25	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference	AQ
15/09/25	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference	AQ
12/09/25	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	AQ
12/09/25	Cocrystal Pharma : 2025 International Calicivirus Conference Presentation	PU
12/09/25	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference	AQ
08/09/25	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment	AQ
03/09/25	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference	AQ
14/08/25	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	AQ
05/08/25	An Oral Pan-viral Protease Inhibitor for the Prevention and Treatment of Norovirus and Coronavirus Infections: Mechanism of Action and Phase 1 Study Results	PU